Lineweaver Wealth Advisors LLC Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)

Lineweaver Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb (NYSE:BMY) in the fourth quarter, HoldingsChannel.com reports. The firm bought 20,603 shares of the biopharmaceutical company’s stock, valued at approximately $1,165,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Nwam LLC grew its position in shares of Bristol-Myers Squibb by 3.1% during the 4th quarter. Nwam LLC now owns 18,473 shares of the biopharmaceutical company’s stock worth $1,045,000 after purchasing an additional 551 shares in the last quarter. NewEdge Wealth LLC boosted its stake in shares of Bristol-Myers Squibb by 23.7% in the fourth quarter. NewEdge Wealth LLC now owns 26,443 shares of the biopharmaceutical company’s stock valued at $1,496,000 after buying an additional 5,073 shares during the period. Whipplewood Advisors LLC acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $82,000. Oregon Public Employees Retirement Fund increased its stake in Bristol-Myers Squibb by 0.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 173,899 shares of the biopharmaceutical company’s stock worth $9,836,000 after acquiring an additional 450 shares during the period. Finally, Checchi Capital Advisers LLC raised its holdings in Bristol-Myers Squibb by 6.9% in the 4th quarter. Checchi Capital Advisers LLC now owns 12,038 shares of the biopharmaceutical company’s stock valued at $681,000 after acquiring an additional 774 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 1,823 shares of the business’s stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $57.34 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a market cap of $116.35 billion, a PE ratio of -12.97, a PEG ratio of 2.07 and a beta of 0.45. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The business has a 50-day simple moving average of $57.06 and a two-hundred day simple moving average of $54.58.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.33%. The ex-dividend date was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is -56.11%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on BMY shares. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Cantor Fitzgerald boosted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.